Abstract:Introduction Yes-associated protein (YAP) is an important transcriptional regulator and effector of the Hippo signaling that has emerged as a novel determinant of malignancy in several human tumors. Verteporfin (VP), a clinically used photosensitizer for treatment of macular degeneration, is recently identified as a potential inhibitor of YAP expression independent of light activation. However, the function and mechanism of Hippo-YAP in diffuse large B-cell lymphoma (DLBCL) remains ill defined. Herein, we investigated the functional significance of YAP and proposed a novel therapeutic strategy for DLBCL. Methods Lymph node biopsies from 60 de novo DLBCL patients and 30 reactive hyperplasia cases were collected with informed consents. The biological function of YAP was evaluated via RNAi-mediated knockdown and CRISPR/Cas9 mediated genomic deletion. RNA-sequencing was conducted to detect the dysregulated RNAs in DLBCL cell with YAP knockout. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways analyses were used to explore the function of these differentially expressed RNAs. SCID-Beige mice were subcutaneously injected with DLBCL cells to establish xenograft model. Animal experiments were performed in accordance with the principles of the Institutional Animal Care. Results We first examined the expression of YAP in Oncomine database and discovered the upregulation of YAP mRNA in DLBCL cells (Fig.1A). High expression of YAP protein was validated in a cohort of newly diagnosed DLBCL patients (n=60). Survival analysis revealed that YAP expression was associated with aggressive disease process (p=0.014, Fig.1B). Functional enrichment analyses of YAP in DLBCL microarray profiles revealed that YAP was enriched in cellular process and biological regulation (Fig. 1C). Knockdown of YAP (shYAP) significantly suppressed cell proliferation and promoted cell cycle arrest (Fig.2A-C). VP restrained proliferation of DLBCL cells in a dose- and time-dependent manner (Fig. 2D). Treatment of VP significantly promoted cell apoptosis and cell cycle arrest in DLBCL cells (Fig. 2E). We next validated the involved mechanism of the anti-tumor effect of VP in DLBCL cells. Protein expression levels of YAP and TEAD were significantly inhibited by VP in dose-dependent manner (Fig.2F). In addition, treatment of VP remarkably restrained the mRNA expression of YAP targeted genes, including CTGF, CYR61 and NF2 (Fig. 2G). Genomic network enrichment of YAP interactions was established in STRING database (Fig. 2H). To validate the involvement of YAP in DLBCL pathogenesis, we deleted YAP expression by CRISPR/Cas9 genomic-editing system. YAP deletion (sgYAP) resulted in significantly reduction in cell proliferation and arrest of cell cycle (Fig.3A). To explore the activities of YAP inhibition in vivo, xenograft DLBCL mice model was established by LY1 cells with YAP-deletion. Compared to the control group, tumors with YAP-deletion displayed reduced growth and decreased expression levels of Ki67 and C-myc (Fig. 3B-C). To further explore the translational regulation mechanism of YAP in DLBCL, integrated analysis of mRNA and non-coding RNA (ncRNA) expression profiles were conducted by whole-transcriptome sequencing (RNA-seq). 158 miRNAs, 29 lncRNAs, 74 circRNAs and 528 mRNAs were shown to be significantly differentially expressed (DE) in DLBCL cells with YAP knockout (Fig. 4A-C). The subsequent GO and KEGG pathway analysis revealed that DE molecules mainly related to cellular metabolic process and pathways. In addition, the miRNA-circRNA network was established (Fig. 4D). Conclusion Taken together, these findings provide in vitro and in vivo pre-clinical evidence for the crucial role of YAP in lymphomagenesis and highlight that blockade of YAP represents an attractive approach in DLBCL. The clinical used photosensitizer Verteporfin exerted anti-tumor effect via disrupting YAP-TEAD complex. Further interrogation on the regulatory mechanism of YAP in DLBCL will outline a promising therapeutic option to utilize this newly identified oncogene in DLBCL therapy. Disclosures No relevant conflicts of interest to declare.

Effect of YAP Inhibition on Human Leukemia HL-60 Cells

Yap Promotes The Proliferation Of Neuroblastoma Cells Through Decreasing The Nuclear Location Of P27(Kip1) Mediated By Akt

Knockdown of the Hippo Transducer YAP Reduces Proliferation and Promotes Apoptosis in the Jurkat Leukemia Cell

Yes-associated protein modulation of human glioma cell growth invitro

Blockade of Yes-Associated Protein As a Novel Therapeutic Approach in Diffuse Large B-Cell Lymphoma

A Potential Role for the Hippo Pathway Protein, Yap, in Controlling Proliferation, Cell Cycle Progression, and Autophagy in Bcpap and Ki Thyroid Papillary Carcinoma Cells

Inactivation of Yap Oncoprotein by the Hippo Pathway is Involved in Cell Contact Inhibition and Tissue Growth Control

The Prognostic Value of YAP1 on Clinical Outcomes in Human Cancers

Knockdown of Yes-Associated Protein Induces the Apoptosis While Inhibits the Proliferation of Human Periodontal Ligament Stem Cells Through Crosstalk Between Erk and Bcl-2 Signaling Pathways

Effect of silencing of Yes-associated protein 1 gene on proliferation and invasion of human non-small cell lung cancer cells

Prognostic Value Of Yes-Associated Protein 1 (Yap1) In Various Cancers: A Meta-Analysis

Overexpression Of Yes-Associated Protein Contributes To Apoptosis Of Lung Cancer

Dysregulated YAP1/Hippo Pathway Contributes to Doxorubicin (ADM) Resistance in Acute Myeloid Leukemia (AML)

LATS1 Promotes B-ALL Tumorigenesis by Regulating YAP1 Phosphorylation and Subcellular Localization

pVHL promotes lysosomal degradation of YAP in lung adenocarcinoma

Knockdown of Yes-Associated Protein Inhibits Proliferation and Downregulates Large Tumor Suppressor 1 Expression in MHCC97H Human Hepatocellular Carcinoma Cells

The Dual Functions of YAP-1 to Promote and Inhibit Cell Growth in Human Malignancy.

Effect of YC-1, a HIF Inhibitor,On Apoptosis of Leukemia Cell.

A Brief Review: Some Compounds Targeting YAP Against Malignancies.

Inhibitory effect of knocking-down Yes-associated protein for the growth of SNB19 glioma cells

[Effects of YAP-small Interfering RNA on the Proliferation and Apoptosis of Human Periodontal Ligament Stem Cells].